Novo Nordisk has launched the first GLP-1 weight-loss pill in the US at a lower price than injections. The once-daily Wegovy pill, approved just before Christmas, is the only GLP-1 tablet currently on the market. Cash-paying patients can access the starting dose for $149 a month, far below typical injectable prices. The pill is expected to broaden appeal due to its needle-free convenience. The launch accelerates competition with Eli Lilly, whose injectable drugs Mounjaro and Zepbound dominate the market. Novo hopes the pill will help regain market share after profit warnings and restructuring. The drug is available through major US pharmacies, telehealth providers, and TrumpRx. Approval outside the US, including in the UK, is still under review.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price War
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Add A Comment
